Company Overview and News

Alloy Resources applies for new ground as it looks to emulate big players like Northern Star

Alloy Resources Limited (ASX:AYR) has applied for new ground south of the company’s Horse Well Gold Project joint venture in Western Australia.
Upvote Downvote

Northern Star spends $23.2m on Echo stake

Gold miner Northern Star Resources has invested $23.2 million in Echo Resources to take a 16.4 per cent stake in the exploration company.
Upvote Downvote

Gold juniors raise $22m

Local gold explorers Echo Resources and Kairos Minerals have raised a combined $22 million from investors to fund ongoing work at their respective projects in Western Australia.
Upvote Downvote

Echo Resources pockets funds to advance Yandal Gold Project

Echo Resources Ltd (ASX:EAR) continues to advance its interests in the world-class Yandal Gold Belt in Western Australia.
Upvote Downvote

Echo Resources’ shares rise on high-grade gold results

Echo Resources’ (ASX:EAR) shares closed circa 5% higher on Thursday after receiving high-grade gold results from drilling at its Zaphod gold discovery in Western Australia.
Upvote Downvote

Echo to raise $5m for gold project

Gold explorer Echo Resources has tapped investors for $5 million to fund ongoing development of its Yandal project near Wiluna.
Upvote Downvote

Echo Resources Ltd’s drilling enhances potential of Orelia gold deposit

Echo Resources Ltd (ASX:EAR) has intersected further significant gold zones from the Orelia gold deposit in the Yandal greenstone belt of Western Australia.
Upvote Downvote

Echo Resources continues to make progress in the Yandal gold belt

Echo Resources (ASX:EAR) is continuing to receive significant gold intersections from drilling at the Empire District in the Yandal gold belt of Western Australia.
Upvote Downvote

Intermin Resources acquires gold project near Kalgoorlie

Intermin Resources (ASX:IRC) has signed a binding agreement to acquire the Anthill gold project located 54 kilometres northwest of Kalgoorlie-Boulder in Western Australia.
Upvote Downvote

Echo Resources strengthens gold portfolio via Metaliko Resources takeover

Echo will now send compulsory acquisition notices to acquire all remaining Metaliko shares not accepted in the takeover bid in accordance with the Corporations Act.
Upvote Downvote

Echo Resources completes major milestone at Julius gold project

Granting of the mining lease follows the completion of various requirements including the signing of the Land Access Native Title Agreement and State Deed with an aboriginal corporation.
Upvote Downvote

Echo, Metaliko confirm $39m merger

Investors have reacted well to news that gold-focused companies Echo Resources and Metaliko Resources will merge in a deal worth $38.9 million.
Upvote Downvote

Metaliko and Echo in tie-up

Echo Resources and Metaliko Resources are expected to announce a tie-up this week, after the two ASX-listed companies with assets in the eastern Goldfields region announced trading halts today.
Upvote Downvote

Echo Resources Ltd to divulge material transaction

Echo Resources Ltd (ASX:EAR) has been granted a trading halt by the ASX this morning, pending details of a material transaction. The halt will remain in place until the opening of trade on Friday 30th September 2016, or earlier if an announcement is made to the market.
Upvote Downvote

Echo Resources Ltd achieves another milestone at Julius Gold Project

Echo Resources Ltd (ASX:EAR) has received standout recoveries ranging from 96.7% to 99.8% gold from a metallurgical test work program at the Julius Project in Western Australia. These results reinforce the recently completed scoping study for Julius which projected positive cash flow of $47 million over 2 years. The Julius project is situated in the Yandal greenstone belt of the Eastern Goldfields, one of Australia’s most bountiful gold regions.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...